Browsing: Pfizer

Pfizer is getting its first taste of the obesity business with partner Sciwind Biosciences as the weight loss drug Ecnoglutide breaks into the Chinese market. But the idea of a consumer-driven market is not new territory for the storied New York pharma, if you look back to erectile dysfunction blockbuster Viagra.

Higher revenue accompanied wider losses, while investor awareness and marketing programs costing approximately C$2.0 million concluded.

The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However Pfizer’s headwinds are easing. Is he right?

With global bond yields high and borrowing costs less forgiving, capital is flowing toward companies that can raise productivity rather than just cut expenses. Transformative AI healthcare stocks sit right in that sweet spot. They use data and algorithms to help doctors work faster and more accurately, which can appeal when every dollar needs to…